Celator Pharmaceuticals (NASDAQ:CPXX) is a clinical stage biopharmaceutical company developing novel formulations of currently approved drugs to treat various cancers. Their delivery platform, CombiPlex, consists of a nano-scale system that combines previously approved chemotherapy agents administered in fixed synergistic ratios. Combining drugs in fixed ratios maximizes the therapeutic response of each drug while maintaining the desired safety profile which is difficult to achieve using current combinational regimens. It allows for prolonged exposure to the drugs without increased toxic effects. CPX-351, Celator's lead formulation, consists of FDA approved Cytarabine and Daunorubicin (1:5 ratio) and is currently in a Phase 3 trial in Acute Myeloid Leukemia (AML). A positive Phase 3 trial can be achieved by demonstrating only...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|
|PRO Top long ideas returned 21.7% in 2016**|